[Federal Register Volume 85, Number 229 (Friday, November 27, 2020)]
[Notices]
[Page 76108]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-26171]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-743]


Bulk Manufacturer of Controlled Substances Application: Novitium 
Pharma LLC

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

-----------------------------------------------------------------------

SUMMARY: Novitium Pharma LLC has applied to be registered as a bulk 
manufacturer of basic class(es) of controlled substance(s). Refer to 
Supplemental Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may file written comments on or objections to 
the issuance of the proposed registration on or before January 26, 
2021. Such persons may also file a written request for a hearing on the 
application on or before January 26, 2021.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this 
is notice that on November 2, 2020, Novitium Pharma LLC, 70 Lake Drive, 
East Windsor, New Jersey 08520, applied to be registered as a bulk 
manufacturer of the following basic class(es) of controlled substances:

------------------------------------------------------------------------
                                           Drug
          Controlled substance             code          Schedule
------------------------------------------------------------------------
Levorphanol.............................    9220  II
------------------------------------------------------------------------

    The company plans to bulk manufacture the above-controlled 
substance to support production of the company's Food and Drug 
Administration approved drug product. No other activity for this drug 
code is authorized for this registration.

William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-26171 Filed 11-25-20; 8:45 am]
BILLING CODE P